13th Annual Cardiovascular Disease Update: TRACK FOUR

13th Annual Cardiovascular Disease Update

Release Date: November 18, 2019
Expiration Date: November 17, 2022

Estimated Time of Completion: This activity is expected to take 1.25 hours to complete.

Program Agenda

TRACK FOUR: MAKING A DIFFERENCE IN PATIENTS WITH VASCULAR DISEASE

Moderators: Heather Gornik, MD and Mehdi Shishehbor, DO, MPH, PhD

Fibromuscular Dysplasia: What Every Cardiovascular Specialist Should Know
Heather Gornik, MD

Management of VTE in 2019: State-of-the-Art Updates
Gregory Piazza, MD, MS

Antithrombotic Therapy for Atherosclerotic Vascular Disease
Schuyler Jones, MD

10-Minute Consult: My Patient Has a Peripheral Bypass Graft for PAD: Are There Things I Have to Do?
Teresa Carman, MD


Faculty

ACTIVITY DIRECTORS

Marco Costa, MD, PhD, MBA
President, UH Harrington Heart & Vascular Institute
Chief Innovation Officer, University Hospitals
Professor, Case Western Reserve University School of Medicine
Dr. Costa reports no financial relationship with a commercial interest relevant to this activity.

Sanjay Rajagopalan, MD
Chief, Division of Cardiovascular Medicine,
UH Harrington Heart & Vascular Institute
Director, Case Cardiovascular Research Institute
Professor, Case Western Reserve University School of Medicine

Dr. Rajagopalan has received honoraria from Janssen, AstraZeneca and Takeda, and the CME Program has determined there is no conflict of interest.

PLENARY SPEAKERS

Deepak Bhatt, MD, MPH
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
Dr. Bhatt has received research funding from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Irowood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, and The Medicines Company, and the CME Program has determined there is no conflict of interest. Presentation will include discussion of unlabeled/investigational uses of a commercial product.

Clyde Yancy, MD
Vice Dean, Diversity & Inclusion
Magerstadt Professor of Medicine, and Professor of Medical Social Sciences
Chief, Division of Cardiology
Northwestern University, Feinberg School of Medicine
Associate Director, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital
Dr. Yancy reports no financial relationship with a commercial interest relevant to this activity.

GUEST SPEAKERS

Robert Brook, MD
Director, Hypertension Center
Professor, Cardiovascular Medicine
University of Michigan Health System
Dr. Brook reports no financial relationship with a commercial interest relevant to this activity.

Anne Curtis, MD
SUNY Distinguished Professor
Charles and Mary Bauer Professor and Chair, Department of Medicine
Jacobs School of Medicine and Biomedical Sciences
University at Buffalo
Dr. Curtis has received honoraria or consulting fees from Abbott, Johnson & Johnson, Novartis AG and Biotronik, and the CME Program has determined there is no conflict of interest. 

James Fang, MD
Chief, Cardiovascular Medicine
Director, Cardiovascular Service Line,
University of Utah Health Care
Professor, University of Utah School of Medicine
Dr. Fang reports no financial relationship with a commercial interest relevant to this activity.

Schuyler Jones, MD
Director, Duke Adult Cardiac Catheterization Laboratories
Associate Professor of Medicine
Duke University and Duke Clinical Research Institute
Dr. Jones has received honoraria from Bayer, Janssen, and Bristol-Myers Squibb, and a research grant from Medtronic, and the CME Program has determined there is no conflict of interest. 

Brian Olshansky, MD
Professor Emeritus of Medicine
University of Iowa Carver College of Medicine
Mercy Heart Center & Vascular Institute
Dr. Olshansky has received honoraria from Lundbeck, Amarin, Respironics and Sanofi Aventis, and the CME Program has determined there is no conflict of interest.

Gregory Piazza, MD, MS
Assistant Professor of Medicine
Harvard Medical School
Brigham and Women’s Hospital
Dr. Piazza has received research funding from Bristol-Myers Squibb, Janssen, BTG, Bayer, Daiichi-Sankyo and Portola, and his partner/spouse has received salary from Boston Scientific, and the CME Program has determined there is no conflict of interest.

Karl Schuleri, MD
Medical Science Liaison
Abiomed
Dr. Schuleri has received salary from Abiomed, and the CME Program has determined there is no conflict of interest. Presentation will include discussion of unlabeled/investigational uses of a commercial product.

Laurence Sperling, MD
Katz Professor in Preventive Cardiology
Director of the Emory Heart Disease Prevention Center
Professor of Global Health
Hubert Department of Global Health
Rollins School of Public Health at Emory University
Dr. Sperling reports no financial relationship with a commercial interest relevant to this activity.

UH SPEAKERS AND PANELISTS

Mauricio Arruda, MD
Director, Electrophysiology Center,
UH Harrington Heart & Vascular Institute
Associate Professor, Case Western Reserve University School of Medicine
Dr. Arruda reports no financial relationship with a commercial interest relevant to this activity.

Guilherme Attizzani, MD
Co-Director, Valve & Structural Heart Disease Center,
UH Harrington Heart & Vascular Institute
Associate Professor, Case Western Reserve University School of Medicine
Dr. Attizzani reports no financial relationship with a commercial interest relevant to this activity.

Hiram Bezerra, MD, PhD
Director, Cardiovascular Imaging Core Laboratory,
UH Harrington Heart & Vascular Institute
Associate Professor, Case Western Reserve University School of Medicine
Dr. Bezerra reports no financial relationship with a commercial interest relevant to this activity.

Teresa Carman, MD
Director, Vascular Medicine and Medical Director, Center for Wound Care
UH Cleveland Medical Center
Director, Anticoagulation Monitoring Service,
UH Harrington Heart & Vascular Institute
Assistant Professor, Case Western Reserve University School of Medicine
Dr. Carman reports no financial relationship with a commercial interest relevant to this activity.

Chantal El Amm, MD
Director, Maternal Cardiology Clinic,
UH Harrington Heart & Vascular Institute
Assistant Professor, Case Western Reserve University School of Medicine
Dr. El Amm reports no financial relationship with a commercial interest relevant to this activity.

Natalie Evans, MD, MS
Division of Cardiovascular Medicine
UH Geauga Medical Center
Clinical Assistant Professor, Case Western Reserve University School of Medicine
Dr. Evans reports no financial relationship with a commercial interest relevant to this activity. 

Heather Gornik, MD
Co-Director, Vascular Center and Director, Fibromuscular Dysplasia & Arterial Dissection Program, UH Harrington Heart & Vascular Institute
Associate Professor, Case Western Reserve University School of Medicine
Dr. Gornik has ownership interest in Flexlife Health, and the CME Program has determined there is no conflict of interest.

Eiran Gorodeski, MD, MPH
UH Harrington Heart & Vascular Institute
Associate Professor, Case Western Reserve University School of Medicine
Dr. Gorodeski has received honoraria and a research grant from Abbott, and the CME Program has determined there is no conflict of interest.

Chris Longenecker, MD
Director, Research & Innovation Center,
UH Harrington Heart & Vascular Institute
Director, HIV Cardio-Metabolic Risk Clinic,
John T. Carey Special Immunology Unit,
UH Cleveland Medical Center
Assistant Professor, Case Western Reserve University School of Medicine
Dr. Longenecker has received research funding from Gilead, and the CME Program has determined there is no conflict of interest.

Judith Mackall, MD
Director, Electrophysiology Fellowship Program,
UH Harrington Heart & Vascular Institute
Associate Professor, Case Western Reserve University School of Medicine
Dr. Mackall has received honoraria from Abbott, and the CME Program has determined there is no conflict of interest.

Guilherme Oliveira, MD, MBA
Director, Advanced Heart Failure & Transplant Center, and Director, Cardio-Oncology Program, UH Harrington Heart & Vascular Institute
Professor, Case Western Reserve University School of Medicine
Dr. Oliveira has received consulting fees from Novartis and Abbott and has served on advisory boards for Abiomed and Pfizer, and the CME Program has determined there is no conflict of interest.

Mehdi Shishehbor, DO, MPH, PhD
Director, Interventional Cardiovascular Center, and Co-Director, Vascular Center,
UH Harrington Heart & Vascular Institute
Professor, Case Western Reserve University School of Medicine
Dr. Shishehbor has received consulting fees from Abbott Vascular, Medtronic, Philips Medical Systems and Terumo Cardiovascular Systems Group, and the CME Program has determined there is no conflict of interest. Presentation will include discussion of unlabeled/investigational uses of a commercial product.

Albert Waldo, MD
Electrophysiology Center, UH Harrington Heart & Vascular Institute
Professor, Case Western Reserve University School of Medicine
Dr. Waldo has received honoraria from Pfizer, consulting fees from AtriCure and Milestone Pharmaceuticals, and has been part of a clinical trial/advisor for Cardiac Insight, and the CME Program has determined there is no conflict of interest.

Planning Committee

Marco Costa, MD, PhD, MBA
Activity Co-Director
Dr. Costa reports no financial relationship with a commercial interest relevant to this activity.

Sanjay Rajagopalan, MD
Activity Co-Director
Dr. Rajagopalan has received honoraria from Janssen, AstraZeneca and Takeda, and the CME Program has determined there is no conflict of interest.

Mauricio Arruda, MD
Dr. Arruda reports no financial relationship with a commercial interest relevant to this activity.

Guilherme Attizzani, MD
Dr. Attizzani reports no financial relationship with a commercial interest relevant to this activity.

Heather Gornik, MD
Dr. Gornik has ownership interest in Flexlife Health, and the CME Program has determined there is no conflict of interest.

Christopher Longenecker, MD
Dr. Longenecker has received research funding from Gilead, and the CME Program has determined there is no conflict of interest.

Judith Mackall, MD
Dr. Mackall has received honoraria from Abbott, and the CME Program has determined there is no conflict of interest.

Guilherme Oliveira, MD
Dr. Oliveira has received consulting fees from Novartis and Abbott and has served on advisory boards for Abiomed and Pfizer, and the CME Program has determined there is no conflict of interest.

Mehdi Shishehbor, DO, MPH, PhD
Dr. Shishehbor has received consulting fees from Abbott Vascular, Medtronic, Philips Medical Systems and Terumo Cardiovascular Systems Group, and the CME Program has determined there is no conflict of interest.

Albert Waldo, MD
Dr. Waldo has received honoraria from Pfizer, consulting fees from AtriCure and Milestone Pharmaceuticals, and has been part of a clinical trial/advisor for Cardiac Insight, and the CME Program has determined there is no conflict of interest.

David Zidar, MD, PhD
Dr. Zidar has received an honorarium from Medtronic and a research grant from AstraZeneca, and the CME Program has determined there is no conflict of interest.

Acknowledgments
Educational grants from Abbott Laboratories, Abiomed, Boston Scientific Corporation and Medtronic are gratefully acknowledged.

Media: Recorded slides and audio presentation.  Supplementary educational materials may include downloads of videos, print materials, slides or web pages.

Target Audience: This program is intended to update practicing internists, family medicine physicians, primary care physicians, cardiologists, cardiac surgeons, vascular surgeons, physician assistants, nurse practitioners, nurses, residents and fellows on current topics in cardiovascular disease.

Learning Objectives
After participating in this activity, participants will be able to:

Accreditation Statement

newlogo2

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Case Western Reserve University School of Medicine designates this enduring material for a maximum of 6 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Track One: 1.25 Credits

Track Two: 1.25 Credits

Track Three: 1.0 Credits

Track Four:  1.5 Credits

Track Five:  1.5 Credits

Disclosure Statement
The policy of Case Western Reserve University School of Medicine CME Program (CWRU CME) requires that the Activity Director, planning committee members and all activity faculty (that is, anyone in a position to control the content of the education activity) disclose to the activity participants all relevant financial relationships with commercial interests.  Where disclosures have been made, conflicts of interest, real or apparent, must be resolved.  Disclosure will be made to activity participants prior to the commencement of the activity.  CWRU CME also requires that faculty make clinical recommendations based on the best available scientific evidence and that faculty identify any discussion of "off-label" or investigational use of pharmaceutical products or medical devices.

Instructions
To receive statements of credit for up to 6 AMA PRA Category 1 Credits™ you must:

  1. Review the full content of the recorded sessions. 
  2. Review any supplementary materials referenced under Resources. 
  3. Reflect on the content. 
  4. Complete the evaluation and claim your credit.

 Your credits will be recorded by the CWRU School of Medicine CME Program and made a part of your cumulative transcript.

Fee
There is no fee for this program.

To contact the CME Provider: E-mail Case Western Reserve University School of Medicine CME at medcme@case.edu

Resources

  1. Willerson, J. T. "The Medical and Device-Related Treatment of Heart Failure." Circulation research 124.11 (2019): 1519.
  2. Choi HM, Park MS, Youn JC. Update on heart failure management and future directions [published correction appears in Korean J Intern Med. 2019 Jul;34(4):944]. Korean J Intern Med. 2019;34(1):11–43. doi:10.3904/kjim.2018.428
  3. Piepoli, Massimo F., et al. "2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)." European heart journal 37.29 (2016): 2315-2381.
  4. Bhatt, Deepak L., et al. "A controlled trial of renal denervation for resistant hypertension." New England Journal of Medicine370.15 (2014): 1393-1401.
  5. Martin, Thomas P., Barbara H. Hanusa, and Wishwa N. Kapoor. "Risk stratification of patients with syncope." Annals of emergency medicine 29.4 (1997): 459-466.
  6. Brouwer, Tom F., et al. "Long-term clinical outcomes of subcutaneous versus transvenous implantable defibrillator therapy." Journal of the American College of Cardiology 68.19 (2016): 2047-2055. 
  7. Kolte, Dhaval, et al. "Vascular teams in peripheral vascular disease." Journal of the American College of Cardiology 73.19 (2019): 2477-2486.
  8. Fox, K. A. A., et al. "Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?." European heart journal(2018).
  9. Khan, Nazish, et al. "11 Oral P2Y12 inhibitors and stemi outcomes: a single centre propensity scored analysis." (2018): A10-A12.
  10. Kapur, Navin, and William O'Neill. "TCT-123 Impact of Gender and Ischemic Time in Anterior STEMIs With Left Ventricular Unloading and Delayed Reperfusion: A Substudy From the STEMI-DTU Safety and Feasibility Trial." Journal of the American College of Cardiology 74.13 Supplement (2019): B122.





Learn More from the 13th Annual Cardiovascular Disease Update:

Track One

Track Two

Track Three

Track Five